SciSparc & Clearmind File 3 New Patents for MDMA, Ibogaine, Ketamine
Ticker: SPRC · Form: 6-K · Filed: Feb 27, 2024 · CIK: 1611746
| Field | Detail |
|---|---|
| Company | Scisparc Ltd. (SPRC) |
| Form Type | 6-K |
| Filed Date | Feb 27, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: patent-application, partnership, pharmaceuticals, R&D
Related Tickers: CMND
TL;DR
**SciSparc and Clearmind just filed 3 new international patents for MDMA, Ibogaine, and Ketamine compounds!**
AI Summary
SciSparc Ltd. announced on February 27, 2024, via a press release, that its partnership with Clearmind has resulted in three new international patent applications. These applications cover significant compounds, specifically MDMA, Ibogaine, and Ketamine. This development highlights advancements in their collaborative research and intellectual property portfolio.
Why It Matters
These new patent applications could secure intellectual property rights for potential future drug formulations involving psychoactive compounds, which may lead to novel treatments and significant market opportunities for both SciSparc and Clearmind if successfully developed and commercialized.
Risk Assessment
Risk Level: medium — While new patent applications are a positive step, they are early-stage developments that do not guarantee successful drug development, regulatory approval, or future revenue, introducing inherent R&D risks.
Key Numbers
- 3 — New International Patent Applications (number of patent applications filed by the SciSparc-Clearmind partnership)
Key Players & Entities
- SciSparc Ltd. (company) — registrant filing the 6-K
- Clearmind (company) — partner in joint patent applications
- MDMA (compound) — subject of new patent applications
- Ibogaine (compound) — subject of new patent applications
- Ketamine (compound) — subject of new patent applications
- February 27, 2024 (date) — date of press release and 6-K filing
FAQ
What is the primary purpose of SciSparc Ltd.'s 6-K filing on February 27, 2024?
The primary purpose is to report that SciSparc Ltd. issued a press release titled "SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds" on February 27, 2024.
Which entities are involved in the partnership mentioned in the press release?
The partnership is between SciSparc and Clearmind, as indicated by the press release title "SciSparc-Clearmind Partnership."
How many new international patent applications were announced?
The press release announced three new international patent applications.
What specific compounds are covered by these new patent applications?
The new international patent applications cover MDMA, Ibogaine, and Ketamine compounds.
What is SciSparc Ltd.'s SEC file number?
SciSparc Ltd.'s Commission file number is 001-38041.
Filing Stats: 319 words · 1 min read · ~1 pages · Grade level 9.1 · Accepted 2024-02-27 08:35:07
Filing Documents
- ea0200777-6k_scisparc.htm (6-K) — 13KB
- ea0200777ex99-1_scisparc.htm (EX-99.1) — 6KB
- 0001213900-24-017161.txt ( ) — 20KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SciSparc Ltd. Date: February 27, 2024 By: /s/ Oz Adler Name: Oz Adler Title: Chief Executive Officer and Chief Financial Officer 3